Thursday, August 28, 2025
Facebook Linkedin Twitter
HomeTagsGenentech

Genentech

Healthcare

Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study

Business Wire -
Genentech, a member of the Roche Group, announced new data from the Phase III IMbrave050 study that show Tecentriq plus Avastin demonstrated a statistically significant...
Healthcare

Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition

Business Wire -
Genentech, a member of the Roche Group announced positive results from the global Phase III COMMODORE 2 study, evaluating the efficacy and safety of...
12Page 2 of 2
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us | Terms & Conditions